Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Overview

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions

B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory
Refractory Non-Hodgkin's lymphoma

Clinical Trials

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

Phase 1

Not yet recruiting

Posted: 2025/05/22

Sponsor:Genentech, Inc.

ID:NCT06984341

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Phase 1

Recruiting

Posted: 2025/05/08

Sponsor:

TILT Biotherapeutics...

ID:NCT06961786

Phase I/II Clinical Trial f CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1

Not yet recruiting

Posted: 2025/05/07

Sponsor:H. Lee Moffitt Cance...

ID:NCT06961357

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2

Not yet recruiting

Posted: 2025/05/02

Sponsor:National Cancer Inst...

ID:NCT06954987

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Not yet recruiting

Posted: 2025/04/23

Sponsor:Mayo Clinic

ID:NCT06940297

FDA Approved Products

Fludarabine phosphate

Manufacturer:Actavis Pharma, Inc.

Route:INTRAVENOUS

Strength:50 mg in 2 mL

Approved: 2023/01/24

NDC:45963-609

Fludarabine Phosphate

Manufacturer:Teva Pharmaceuticals, Inc.

Route:INTRAVENOUS

Strength:25 mg in 1 mL

Approved: 2023/07/25

NDC:0480-9772

Fludarabine Phosphate

Manufacturer:Lannett Company, Inc.

Route:INTRAVENOUS

Strength:25 mg in 1 mL

Approved: 2022/09/13

NDC:0527-1242

FLUDARABINE PHOSPHATE

Manufacturer:Accord Healthcare, Inc.

Route:INTRAVENOUS

Strength:25 mg in 1 mL

Approved: 2022/11/24

NDC:16729-131

Fludarabine Phosphate

Manufacturer:Sagent Pharmaceuticals

Route:INTRAVENOUS

Strength:25 mg in 1 mL

Approved: 2021/07/22

NDC:25021-242

Singapore Approved Products

FLUDARA FOR INTRAVENOUS INJECTION 50 mg/vial

Manufacturer:INTENDIS MANUFACTURING SPA, BAXTER ONCOLOGY GmbH

Form:INJECTION, POWDER, FOR SOLUTION

Strength:50 mg/vial

Online:Yes

Approved: 1999/10/05

Approval:SIN11143P

FLUDARABINE PHOSPHATE POWDER FOR SOLUTION FOR INJECTION/ INFUSION USP

Manufacturer:Fresenius Kabi Oncology Limited

Form:INJECTION, POWDER, FOR SOLUTION

Strength:50 mg/ vial

Online:Yes

Approved: 2016/06/08

Approval:SIN15030P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy

Drug Development Updates

Fludarabine

Overview

Background

Indication

Associated Conditions

Clinical Trials

FDA Approved Products

Singapore Approved Products

Related News

CAR T-Cell Therapy AUTO4 Shows Promise in Treating Peripheral T-Cell Lymphoma

Cabaletta Bio's Rese-cel Shows Promising Results in Multiple Autoimmune Diseases, Achieving Drug-Free Remission

Peri-Transplant Ruxolitinib Significantly Reduces GVHD Risk in Myelofibrosis Patients

Third-Generation CAR T-Cell Therapy Shows Promise in Relapsed/Refractory CLL

Imugene Doses First Australian Patient in Phase 1b Trial of Azer-Cel for B-Cell Lymphoma

Drug Development Updates